文献速递乳腺癌放疗

接受放射治疗的乳腺癌女性的经济毒性:前瞻性观察研究的最终结果

Financial Toxicity in Women With Breast Cancer Receiving Radiation Therapy: Final Results of a Prospective Observational Study.
PubMed 文献 · Pract Radiat Oncol · 2021-12-09

该前瞻性观察研究纳入108例接受放疗的I–III期乳腺癌女性,放疗完成后1个月内完成COST、FACT-G7及经济毒性问卷。平均COST评分为28.6,平均FACT-G7为18.4;在中长程放疗患者(n=98)中,婚姻状况、药物费用、就业类型和手术方式与COST评分显著相关(均P<.05),放疗时长与COST无关(P=.79),COST与FACT-G7强相关(P<.0001)。

要点

  • 108例I–III期乳腺癌患者放疗后完成COST评分,平均COST为28.6,平均FACT-G7为18.4。
  • 中长程放疗患者(n=98)中,婚姻、药物费用、就业类型和手术方式与COST评分显著相关(均P<.05)。
  • 放疗时长与COST评分无关(P=.79),COST与FACT-G7强相关(P<.0001)。

核心结论

  • 在接受放疗的乳腺癌女性前瞻性研究中,包括手术方式在内的不同因素与经济毒性显著相关,经济毒性与健康相关生活质量强相关。
  • 作者认为,进一步刻画接受放疗的乳腺癌女性经济毒性与健康相关生活质量的关系并明确经济毒性的临床预测因素,可能有助于指导未来研究,探索针对经济毒性高风险乳腺癌患者的最佳靶向干预。

研究设计与样本

  • 前瞻性观察研究,连续纳入I–III期乳腺癌患者,在放疗完成后1个月内完成FACT-G7、定制经济毒性问卷和COST评分。
  • 108例入组患者具备完整COST评分可分析,其中接受长程、中程和短程放疗者分别为56例、42例和10例。
  • 采用两样本t检验和χ2检验进行组间比较,Pearson相关分析COST与FACT-G7,线性和多元回归评估COST预测因素。

主要发现

  • 平均COST评分为28.6,平均FACT-G7为18.4;FACT-G7(范围0–28)和COST(范围0–44)评分越低分别表示生活质量和经济毒性越差。
  • 在中程和长程放疗患者(n=98)中,多元分析显示婚姻状况(已婚相对其他状态COST更高)、药物费用(无显著药物费用相对有显著药物费用COST更高)、就业类型(残疾或失业相对在职COST更低,退休相对在职COST更高)和手术方式(肿块切除相对乳房切除COST更高)与COST评分显著相关,均P<.05。
  • 放疗时长分组与COST无关(P=.79);COST与FACT-G7在总体队列中强相关(P<.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to quantify financial toxicity (FT) present in a prospective cohort of women with breast cancer (BC) receiving radiation therapy (RT), identify predictors of FT, correlate FT with health-related quality of life (QoL), and determine whether duration of RT is associated with FT. METHODS AND MATERIALS: Consecutive patients with stage I-III BC completed Functional Assessment of Cancer Therapy-G7 (FACT-G7), a tailored FT questionnaire, and Comprehensive Score for Financial Toxicity (COST) scoring within 1 month of RT completion. Lower scores on FACT-G7 (range, 0-28) and COST (range, 0-44) indicate worse QoL and FT. Group comparisons were performed with a 2-sample t test and χ2 tests for continuous and categorical variables, respectively. Pearson correlation was used to associate COST with FACT-G7. Linear and multiple regression were used to evaluate predictors of COST. RESULTS: One hundred eight enrolled patients were eligible for analysis with completed COST scores, including 56, 42, and 10 patients treated with long-, intermediate-, and short-course RT. Mean COST score was 28.6 and mean FACT-G7 was 18.4. Among patients treated with intermediate- and long-course RT (n = 98), marital status (higher COST associated with married status relative to other), medication cost (higher COST for no significant medication costs relative to significant medication costs), employment type (lower COST associated with disabled status or unemployed, higher COST with retired status relative to working), and surgery type (higher COST for lumpectomy relative to mastectomy) were significantly associated with COST score by multivariable analysis (all P values < .05). RT length group was not associated with COST (P = .79). COST and FACT-G7 were strongly correlated for the overall cohort (P < .0001). CONCLUSIONS: In this prospective study of women with BC receiving RT, distinct factors including surgery type were significantly associated with FT. FT was strongly correlated with health-related QoL. Increased characterization of the relationship between FT and health-related QoL for women with BC receiving RT and defining clinical predictors of FT may help guide future studies investigating optimal targeted interventions for patients with BC at high risk for FT.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yusuf M, Pan J, Rai SN, et al. Financial Toxicity in Women With Breast Cancer Receiving Radiation Therapy: Final Results of a Prospective Observational Study. Pract Radiat Oncol. 2021. PMID: 34896597. doi:10.1016/j.prro.2021.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。